3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Carcinogenesis
1
Interventions
Gemcitabine
17
pembrolizumab
16
Cisplatin
14
enfortumab vedotin
7
avelumab
7
Nivolumab
6
Docetaxel
6
atezolizumab
5
Paclitaxel
5
Cystectomy
5
sacituzumab govitecan
4
durvalumab
4
Mitomycin
4
Cystoscopy
4
Carboplatin
4
vofatamab
3
tremelimumab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
vinflunine
2
tisotumab vedotin
2
poly ICLC
2
cemiplimab
2
aldesleukin
2
Transurethral Resection of Bladder
2
Radiotherapy, Intensity-Modulated
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Clinical Trials, Phase II as Topic
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Urinary Bladder Neoplasms
×
Monatide (IMS 3015)
×
Clear all
NCT04106115
2024-12-04
DURANCE
University College, London
Phase 1/2
Recruiting
64 enrolled